Hawaii Biotech has acquired a family of patents to West Nile virus vaccine technology in a nonexclusive pharma licensing pact related technologies from Merck, a big pharma company.
Terms of the pharma licensing deal were not disclosed.
"This transaction will enable HBI to continue the development of our vaccine for West Nile virus, an important emerging infectious disease," said Elliot Parks, Hawaii Biotech CEO, calling it “a significant milestone.”
"We appreciate the cooperation we have received from Merck, and we look forward to continuing the clinical development of this vaccine candidate."
The company is developing a Crimean-Congo Hemorrhagic fever vaccine through a grant from the National Institute of Allergy and Infectious Diseases.
Other vaccines also under development include a malaria vaccine in collaboration with academic researchers at the University of Hawaii at Manoa, and a tick-borne flavivirus vaccine.
For further deal information visit Current Agreements (subscription required)
Read: more on Merck company profile, recent partnering, M&A and financing news and articles
Report: Partnering Deals and Alliances with Merck & Co
Related report: Partnering Deals and Alliances with Big Pharma
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity